🔗 Permalink

Inventor profile of:

Jun Tan

City:

Tampa, Florida

Country:

United States

Published Applications:

Last publication date:

2021-02-04

Top Assignees for applications by Jun Tan

The entities that hold a legal rights for patent applications filed by inventor Tan Jun:

UNIVERSITY OF SOUTH FLORIDA 27 Tampa, FL United States
Natura Therapeutics, Inc. 3 Tampa, FL United States
UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) 1 TAMPA, FL United States
Uinversity of South Florida 1 Tampa, FL United States
The Department of Veterans' Affairs 1 Washington, DC United States
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 1 Washington, DC United States
The Unites States of America as Represented by the Department of Veterans Affairs Office of General Counsel—PSG IV (024) 1 Washington, DC United States

Recent patent applications by Tan Jun

Jun Tan from Tampa, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-02-04

US20210030770A1

Human necessities

LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS

#2 | 2020-04-30

US20200129527A1

Human necessities

Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders

#3 | 2019-06-20

US20190185544A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS OF MODULATING ABETA PROTEIN

#4 | 2018-11-15

US20180325950A1

Human necessities

HUCBC TREATMENT OF AMYLOID-ASSOCIATED DISEASE

#5 | 2018-01-25

US20180021456A1

Human necessities

SELF-ASSEMBLED TARGETED INCLUSION COMPLEXES FOR DRUG DELIVERY

#6 | 2017-11-28

US14291773

Human necessities

Compositions and methods of improving cognitive performance

#7 | 2017-08-10

US20170224724A1

Human necessities

Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome

#8 | 2017-05-25

US20170143769A1

Human necessities

HUMAN UMBILICAL CORD BLOOD-DERIVED MONOCYTES FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS

#9 | 2017-02-16

US20170044225A1

Chemistry; metallurgy

Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use

#10 | 2016-11-24

US20160339055A1

Human necessities

Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders

#11 | 2016-10-20

US20160303165A1

Human necessities

HUCBC treatment of amyloid-associated disease

#12 | 2016-04-21

US20160106997A1

Human necessities

Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment

#13 | 2015-06-11

US20150157597A1

Human necessities

NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION

#14 | 2015-06-04

US20150153330A1

Physics

sAPP-alpha as a Biomarker for Prediction of Inflammatory and Autoimmune-Related Disorders

#15 | 2014-12-09

US12768380

Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG)

#16 | 2014-08-12

US12421342

Flavonoid treatment of glycogen synthase kinase-based disease

#17 | 2014-07-15

US12020214

Chemistry; metallurgy

Treatment of glycogen synthase kinase-based disease

#18 | 2014-02-06

US20140038913A1

Human necessities

Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism

#19 | 2013-10-31

US20130291135A1

Human necessities

TRANSGENIC MODEL OF ALZHEIMER'S DISEASE

#20 | 2013-10-03

US20130261045A1

Human necessities

GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE

#21 | 2013-08-22

US20130217045A1

Physics

Use of Functional Autoantibodies in Alzheimer Disease

#22 | 2013-06-27

US20130165339A1

Physics

SAPP-ALPHA AS A BIOMARKER FOR PREDICTION OF INFLAMMATORY AND AUTOIMMUNE-RELATED DISORDERS

#23 | 2012-03-15

US20120065456A1

Human necessities

Prevention and treatment of alzheimer'S disease through electromagnetic field exposure

#24 | 2011-08-30

US12727679

Generation of transgenic human soluble amyloid precursor protein alpha expressing mice

#25 | 2011-08-18

US20110201565A1

Human necessities

LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM

#26 | 2011-02-17

US20110038963A1

Human necessities

Combined effects of nutrients on proliferation of stem cells

#27 | 2010-10-21

US20100267733A1

Human necessities

Synergistic Modulation of Microglial Activation by Nicotine and THC

#28 | 2010-06-17

US20100150882A1

Human necessities

HUCBC treatment of amyloid associated disease

#29 | 2010-03-18

US20100069479A1

Human necessities

NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION

#30 | 2010-02-18

US20100040558A1

Human necessities

GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE

#31 | 2009-11-12

US20090280198A1

Human necessities

Combined effects of nutrients on proliferation of stem cells

#32 | 2008-04-17

US20080089905A1

Human necessities

COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH)

#33 | 2008-04-10

US20080085330A1

Human necessities

COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING SPIRULINA

#34 | 2008-02-07

US20080033038A1

Human necessities

Compositions of polyphenols and methods of use

#35 | 2007-07-12

US20070160615A1

Chemistry; metallurgy

Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease

#36 | 2006-12-07

US20060275512A1

Human necessities

Combined effects of nutrients on proliferation of stem cells

#37 | 2006-10-05

US20060223790A1

Human necessities

Modulation of Microglial by Nicotinic Medications

InventorID:

313331 ⎘